BridgeBio Pharma
BBIO
76.03
-2.15
-2.75%
BridgeBio Pharma
US · BBIO
#1254 by market cap
Listed 2019
76.03
-2.15
-2.75%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:01
Recent news
-
Rating change
CCORF Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $106Market Newswire · 2026/10/7
-
Morgan Stanley Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Raises Target Price to $91Market Newswire · 2026/11/13
-
Rating change
Wells Fargo Initiates BridgeBio Pharma(BBIO.US) With Buy Rating, Announces Target Price $102Market Newswire · 2026/10/15
-
Rating change
H.C. Wainwright Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $120Market Newswire · 2026/10/16
-
CCORF Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Raises Target Price to $108Market Newswire · 2026/11/2
-
Rating change
RBC Capital Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $100Market Newswire · 2026/10/9
-
Rating change
Citi Maintains BridgeBio Pharma(BBIO.US) With Hold Rating, Maintains Target Price $91Market Newswire · 2026/10/21
-
Rating change
UBS Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $92Market Newswire · 2026/10/15
-
Rating change
Morgan Stanley Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Cuts Target Price to $87Market Newswire · 2026/10/21
-
Rating change
A Quick Look at Today's Ratings for BridgeBio Pharma(BBIO.US), With a Forecast Between $88 to $130Market Newswire · 2026/10/31
-
Rating change
Cantor Fitzgerald Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $110Market Newswire · 2026/10/26
-
Rating change
Piper Sandler Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Raises Target Price to $120Market Newswire · 2026/10/19
-
Rating change
BofA Securities Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Cuts Target Price to $102Market Newswire · 2026/10/19
-
Barclays Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $156Market Newswire · 2026/11/2
-
Rating change
A Quick Look at Today's Ratings for BridgeBio Pharma(BBIO.US), With a Forecast Between $91 to $120Market Newswire · 2026/10/30
-
Rating change
Morgan Stanley Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $87Market Newswire · 2026/10/22
-
Rating change
Citi Maintains BridgeBio Pharma(BBIO.US) With Hold Rating, Cuts Target Price to $91Market Newswire · 2026/10/19
-
Piper Sandler Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $120Market Newswire · 2026/11/20
-
BridgeBio Pharma(BBIO.US) Officer Sells US$4.28 Million in Common StockMarket Newswire · 2026/11/21
-
Rating change
UBS Initiates BridgeBio Pharma(BBIO.US) With Buy Rating, Announces Target Price $92Market Newswire · 2026/10/15
-
Rating change
A Quick Look at Today's Ratings for BridgeBio Pharma(BBIO.US), With a Forecast Between $104 to $156Market Newswire · 2026/10/7
-
Rating change
Barclays Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $157Market Newswire · 2026/9/30
-
Earnings Flash (BBIO) BridgeBio Pharma Posts Q3 Per-Share Loss $0.42, Vs. FactSet Est of $0.54 LossMT Newswires · 2026/10/30
-
Rating change
Piper Sandler Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $115Market Newswire · 2026/8/31
-
Rating change
TD Cowen Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $110Market Newswire · 2026/9/24
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 20:01:24 · For reference only, not investment advice and not tailored to your situation.
BridgeBio Pharma discussion 0 comments